Company intelligence / Profile preview

Nirmidas Biotech

Mountain View, California, USA

Ownership: Private
Development stage: Other

Overview

Nirmidas Biotech develops and commercializes plasmonic gold (pGOLD) assay platforms, near‑infrared imaging systems, and NIR dyes/probes for research and clinical diagnostic applications, including multiplexed COVID‑19 antibody and antigen tests and high‑sensitivity biomarker detection tools.[1][2][4][7][9]

Therapeutic areas: ImmunologyCardiovascularNeurologyInfectious DiseasesOncology
Modalities: DeviceRecombinant proteinAntibodyNanoparticleSmall molecule
Industry: Protein Biomarker Diagnostics

Partnerships

Janssen Labs (JLABS) program membership[1][5]QB3 program membership[1]Stanford StartX Med Program membership[1]MIT Industrial Liaison Program (MIT ILP) membership[1]Licensing of NIR-II probes and nanoparticles from Stanford University[4][7]

Beyond the preview

Go deeper on Nirmidas Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nirmidas Biotech.

Explore the full profile